by The preterm birth and PROM testing market involves various processes and products used to detect preterm birth risks and diagnose premature rupture of membranes (PROM). Preterm birth refers to the birth of a baby at least three weeks before the due date or 37 weeks gestation. PROM testing helps identify women who are at risk of preterm delivery and those requiring close monitoring and antibiotics treatment. The preterm birth test kit analyses fetal fibronectin from the cervicovaginal secretions, while the PROM test involves AmniSure ROM test and nitrazine test to detect rupture of amniotic sac and fluid leakage.
The Global Preterm Birth And PROM Testing Market Size is estimated to be valued at US$ 1.95 Mn in 2024 and is expected to exhibit a CAGR of 4.7% over the forecast period 2024 to 2031.
Rising incidences of preterm births and the increasing use of fetal fibronectin testing to identify at-risk pregnancies are fueling market growth. Fetal fibronectin testing is a rapid, reliable and low-cost screening method for detecting premature births. It helps reduce healthcare costs by only monitoring women with a positive test result. Moreover, growing awareness about complications of preterm births and availability of advanced diagnostic technologies is propelling the uptake of preterm birth and PROM tests globally.
Key Takeaways
Key players operating in the preterm birth and PROM testing market are Sanofi S.A., AbbVie Inc., Perrigo Company PLC, 3M, Lee’s Pharmaceutical Holdings Ltd, Cassiopea, Glenmark Pharmaceuticals, Bausch Health, and Novartis International AG.
The rising preterm birth rate across both developed and developing nations is spurring demand for advanced diagnostic testing. According to the WHO, prematurity is the leading cause of death among children under 5 years of age, accounting for approximately 1 million deaths in 2015.
Global expansion strategies of major market players such as partnerships, acquisitions and new product launches in high growth markets will further support the market revenue growth during the forecast period. For instance, in 2019, Hologic launched its PROM 1 pH FAST fecal occult blood test in countries outside the United States.
Market Key Trends
Increasing applications of fetal fibronectin testing is a major trend in the preterm birth and PROM testing market. Fetal fibronectin, a glycoprotein produced by fetal membranes, can be detected in cervicovaginal secretions from 16 weeks of pregnancy onwards using rapid immunoassays. A negative fibronectin result at or after 22–24 weeks reliably predicts the absence of preterm delivery within 7–14 days with high accuracy of over 95%. As such, fetal fibronectin tests are being increasingly used in clinical practice for managing high-risk pregnancies and identifying women who require close monitoring and intervention. This minimizes unnecessary monitoring and allows focusing treatment on at-risk cases only.
Porter’s Analysis
Threat of new entrants: There is moderate threat of new entrants as the market requires development of advanced diagnostic technologies and adhering to strict regulatory guidelines.
Bargaining power of buyers: Buyers have moderate bargaining power due to presence of multiple regional players offering substitutable diagnostic solutions.
Bargaining power of suppliers: Suppliers have low to moderate bargaining power given technological expertise required and established buyer relationships of existing market players.
Threat of new substitutes: Threat of substitutes is low as no close alternative is available for accurate preterm birth prediction and testing.
Competitive rivalry: The market witnesses high competition due to presence of major regional and global players offering innovative diagnostic solutions.
Geographical Regions
North America holds the major share in the global preterm birth and prom testing market in terms of value due to high incidences of preterm births, improved healthcare infrastructure, rising adoption of advanced diagnostic technologies, and presence of key market players in the region.
Asia Pacific is expected to witness the fastest growth over the forecast period owing to increasing awareness, growing healthcare expenditure, rising per capita income, and expanding patient base due to growing geriatric population.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
